Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.
) pushed the Drugs industry higher today making it today's featured drugs winner. The industry as a whole closed the day up 0.9%. By the end of trading, Questcor Pharmaceuticals rose $1.23 (2.2%) to $57.76 on average volume. Throughout the day, 1,757,394 shares of Questcor Pharmaceuticals exchanged hands as compared to its average daily volume of 2,051,900 shares. The stock ranged in a price between $56.33-$57.87 after having opened the day at $56.71 as compared to the previous trading day's close of $56.53. Other companies within the Drugs industry that increased today were:
), up 20.6%,
), up 17.3%,
), up 15.5% and
), up 11.3%.
- EXCLUSIVE OFFER: Jim Cramer's Protégé, Dave Peltier, only buys Stocks Under $10 that he thinks could potentially double. See what he's trading today with a 14-day FREE pass.
Questcor Pharmaceuticals, Inc., a biopharmaceutical company, provides drugs for the treatment of multiple sclerosis, nephrotic syndrome, and infantile spasms indications. It primarily offers H.P. Questcor Pharmaceuticals has a market cap of $3.4 billion and is part of the health care sector. The company has a P/E ratio of 13.0, below the S&P 500 P/E ratio of 17.7. Shares are up 110.5% year to date as of the close of trading on Tuesday. Currently there are 6 analysts that rate Questcor Pharmaceuticals a buy, no analysts rate it a sell, and 1 rates it a hold.
TheStreet Ratings rates
. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures, solid stock price performance, impressive record of earnings per share growth and compelling growth in net income. Although the company may harbor some minor weaknesses, we feel they are unlikely to have a significant impact on results.
- You can view the full Questcor Pharmaceuticals Ratings Report.
On the negative front,
), down 39.4%,
), down 15.5%,
), down 8.6% and
), down 6.2% , were all laggards within the drugs industry with
) being today's drugs industry laggard.
- Use our drugs section to find industry-relevant news.
- Or find some new ideas from our top rated stocks lists.
For investors not wanting singular stock exposure, ETFs may be of interest. Investors who are bullish on the drugs industry could consider
) while those bearish on the drugs industry could consider
- Find other investment ideas from our top rated ETFs lists.